Active Recombinant Human PCSK9 Protein, His & Avi-tagged, Biotinylated

• Cat.No.: PCSK9-352H
• Product Overview: Recombinant Human PCSK9 Protein, His & Avi-tagged, Biotinylated is expressed from human HEK293 cells. It contains AA Gln 31 - Gln 692 (Accession # AAI66619). Predicted N-terminus: Gln 31. This protein carries an Avi tag at the C-terminus, followed by a polyhistidine tag. The protein has a calculated MW of 72.0 kDa. The protein migrates as 20 kDa and 66 kDa on a SDS-PAGE gel under reducing (R) condition due to glycosylation and proteolytic digestion. The biotin to protein ratio is 0.5-1 as determined by the HABA assay.

Specification

• Source: HEK293
• Species: Human
• Tag: His&Avi
• Form: Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
• Bio-activity: Immobilized Human LDL R, His Tag at 10 μg/mL (100 μL/well) can bind Recombinant Human PCSK9 Protein, His & Avi-tagged, Biotinylated with a linear range of 2-31 ng/mL (QC tested).
  Recombinant Human PCSK9 Protein, His & Avi-tagged, Biotinylated can bind anti-Human PCSK9 Mab, Human IgG1 with a linear range of 0.05-1.5 ng/mL. The biotinylated PCSK9 is coated at 1 ug/mL (100 uL/well) on a streptavidin coated plates (Routinely tested).
  Immobilized Human VLDL R, His Tag at 5 μg/mL (100 μL/well) can bind Recombinant Human PCSK9 Protein, His & Avi-tagged, Biotinylated with a linear range of 10-156 ng/mL (Routinely tested).
  FACS analysis shows that Biotinylated Human PCSK9, His Tag (Cat. No. PC9-H82E7) inhibits LDL uptake in HepG2 cells. The EC50 for this effect is 1.502-2.378 μg/mL.
• Molecular Mass: 72.0 kDa
• Protein length: Gln 31 - Gln 692
• Endotoxin: Less than 1.0 EU per μg by the LAL method.
• Purity: >92% as determined by reduced SDS-PAGE.
• Notes: Please avoid repeated freeze-thaw cycles.
• Stability: No activity loss is observed after storage at:
  4-8 centigrade for 12 months in lyophilized state;
  -70 centigrade for 3 months under sterile conditions after reconstitution.
• Storage: For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 mg/ml. Centrifuge the vial at 4 centigrade before opening to recover the entire contents.

Gene Information

• Gene Name: PCSK9 proprotein convertase subtilisin/kexin type 9 [ Homo sapiens ]
• Official Symbol: PCSK9
• Synonyms: PCSK9; proprotein convertase subtilisin/kexin type 9; FH3; NARC 1; NARC1; NARC-1; HCHOLA3
• Gene ID: 353175
• MIM: 607786
• UniProt ID: Q8NBP7

Reviews

11/13/2022

In immunological experiments, it was found that it had good antigenicity and could induce target immune responses.

07/07/2022

It promoted cell growth and proliferation.

03/04/2022

High catalytic efficiency.

Q&As

Is there a relationship between genetic mutations in the PCSK9 protein and cardiovascular disease?

Yes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.

How can PCSK9 protein be used for vaccine development?

PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.

What is the relationship between PCSK9 protein and obesity?

This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.

What are the new prospects for future therapies that inhibit PCSK9 protein?

Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.

What drugs are currently available to inhibit the PCSK9 protein?

Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.

What is the relationship between PCSK9 protein and hypercholesterolemia?

PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.